On the 8th, the first batch of prescriptions for innovative lipid-lowering drugs were issued in Guangzhou, Shanghai, Beijing and other places, bringing a new option of original imported combined lipid-lowering drugs to cardiovascular disease patients. On the same day, the innovative lipid-lowering single tablet compound preparation Yilituo (generic name: ezetimibe atorvastatin calcium tablets (II)) under the umbrella of Eucalyptus was prescribed in hospitals such as Fuwai Hospital of the Chinese Academy of Medical Sciences, Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine, Beijing United Family Hospital, and Guangzhou United Family Hospital, which is expected to help more patients with dyslipidemia benefit from lipid-lowering standards. Currently, cardiovascular disease remains the leading cause of death among residents in China. In the prevention and treatment of atherosclerotic cardiovascular disease, reducing LDL cholesterol is the key. Faced with the current situation of high incidence, low treatment rate, and low compliance rate in blood lipid management, it is urgent for clinical practice to find treatment plans that are suitable for the development of diseases in China, and to help patients with different conditions of blood lipid abnormalities solve problems in a targeted manner Professor Li Jianjun from Fuwai Hospital, Chinese Academy of Medical Sciences, pointed out that "in recent years, the combination use of lipid-lowering drugs has become a basic trend in clinical lipid management. Innovative lipid-lowering single tablet compound preparations have further enriched the options for combination therapy, which is of great significance for improving patients' lipid-lowering compliance rate." In addition, lipid management focuses on long-term standardized medication, but "difficulty in adhering" has become a major obstacle in the lipid-lowering treatment process. Especially for patients with dyslipidemia complicated with hypertension, diabetes and other diseases, the drugs that need to be taken every day are often "one large handful", which is easy to forget to take, miss to take and other phenomena, leading to reduced treatment compliance and increased risk of cardiovascular events. Professor Chen Zhenyue from Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine said, "In clinical lipid management, treatment compliance has always been one of the main challenges. Single tablet compound preparations such as ezetimibe atorvastatin calcium tablets bring new choices for lipid-lowering treatment and promote long-term standardized medication. We look forward to the continuous improvement of the overall prevention and treatment level of cardiovascular disease in China with the help of more innovative treatments." "" For patients with abnormal blood lipids, achieving lipid-lowering standards is a key measure to prevent and treat cardiovascular disease, "said Shen Farong, the president of Zhejiang Qiushi Cardiovascular Hospital." As a beneficial supplement to public medical services, social medical institutions not only provide basic medical and health services, but also help provide patients with more comprehensive treatment plans to meet the needs of the public. The demand for hierarchical and diversified health services